Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 4Unknown 2Recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Other hematologic neoplasm 4

Conditions

Multiple Myeloma 363Precursor Cell Lymphoblastic Leukemia-Lymphoma 89Leukemia 61Neoplasms, Plasma Cell 60Lymphoma 59Recurrence 52Neoplasms 34Vomiting 33Lymphoma, Non-Hodgkin 32Immunoglobulin Light-chain Amyloidosis 27Lymphoma, Mantle-Cell 26Burkitt Lymphoma 26Nausea 22Lymphoma, Large B-Cell, Diffuse 21Leukemia, Lymphocytic, Chronic, B-Cell 21Waldenstrom Macroglobulinemia 19Prostatic Neoplasms 19Lymphoma, Follicular 18Hodgkin Disease 18Neoplasm Metastasis 14Breast Neoplasms 14Amyloidosis 12Lymphoma, B-Cell, Marginal Zone 11Leukemia, Myeloid, Acute 11Carcinoma, Non-Small-Cell Lung 11Ovarian Neoplasms 9Lymphoma, Large-Cell, Immunoblastic 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell, Cutaneous 8Colonic Neoplasms 8

Interventions

fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 6Melphalan 6Whole-Body Irradiation 5Tacrolimus 5Mycophenolic Acid 5Dexamethasone 4Cyclophosphamide 4fludarabine 3filanesib 3Bortezomib 3ixazomib 2Steroids 2Sirolimus 2Lenalidomide 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Cytarabine 2Carmustine 2Antilymphocyte Serum 2pomalidomide 1merphos 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carmustine, poliferprosan 20 drug combination 1carfilzomib 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Leukemia, Plasma Cell × Dexamethasone × Clear all
NCT02547662 2023-10-30

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

Mayo Clinic

Phase 2 Completed
17 enrolled 13 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Plasmacytoma

NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT01553357 2012-03-14

Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia

IRCCS Centro di Riferimento Oncologico della Basilicata

Phase 2 Completed
23 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡